September, 2023

InSysBio announces its participation in SITC's 38th Annual Meeting (the Society for Immunotherapy of Cancer) which is to be held on November 1 - 5, 2023 at San Diego Convention Center, San Diego, California or Virtual. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1133 and 6 posters in frames of the Meeting, namely:

• 338 "Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies via mathematical modeling" by Oleg Demin Jr¹, Galina Kolesova², Natalia Ramos Hernandez³, Thomas Faitg³, Stefan Zajic³, Lourdes Cucurull-Sanchez⁴

Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK

• 354 "Optimization of dose and regimen of letetresgene autoleucel for the treatment of synovial sarcoma: simulation of dose dependence and split dosing using quantitative systems pharmacology modeling" by Oleg Demin Jr¹, Galina Kolesova², Stefan Zajic³, Lourdes Cucurull-Sanchez⁴

Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK

• 480 "Translational PK/RO model of tetravalent bispecific antibody CTX8371: receptor occupancy estimation, PD1 loss and bispecific binding-related avidity increase in low doses" by Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin

• 874 "A Quantitative Systems Pharmacology model of head and neck squamous cell carcinoma: a tool for evaluating treatment outcomes for combination therapies" by Alexandra Diakonova¹, Sergey Smirnov¹, Anna Roskoshnaia¹, Ivan Borisov¹, Oleg Demin², Gaurav Bajaj³, Homer Adams III³, Maria Jure-Kunkel³, Manish Gupta³, Craig Thalhauser³

Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, N

• 1167 "Prediction of first-in-human dose for HPN536, a T-cell engager targeting mesothelin: MABEL vs mechanistic translational PK/RO/PA modeling" by Oleg Demin Jr, Dmitry Shchelokov

• 1280 "Modeling of direct (EGFR- based) and ADCC cytotoxic effect of Cetuximab on the basis of literature available in vitro data" by Oleg Demin², Sergey Smirnov¹, Alexandra Diakonova¹, Anna Roskoshnaya¹, Gaurav Bajaj³, Homer Adams III³, Manish Gupta³, Craig Thalhauser³

Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro N

Check out our Booth #1133 at SITC 2023!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share